Robles-Díaz G, Díaz-Sánchez V, Fernández-del Castillo C, Morales M, Aceves G, Galván E, Altamirano A
Pancreas Clinic, Instituto Nacional de La Nutrición Salvador Zubirán, Mexico City, Mexico.
Am J Gastroenterol. 1991 May;86(5):591-4.
The testosterone:dihydrotestosterone ratio (T:DHT) and the antigenic marker CA 19-9 were studied in the serum of 21 male patients with pancreatic cancer and 62 controls with other gastrointestinal malignancies or benign pancreatobiliary disease. Specificity of the T:DHT ratio was 98%, significantly better than the specificity of CA 19-9 at both a 37 U/ml cutoff level (61%) and at 100 U/ml (79%). Sensitivity of the T:DHT ratio was 67%, and that of CA 19-9, 71% and 90% at the upper and lower cutoff levels, respectively. False-negative results of the T:DHT ratio were found predominantly in cases of advanced pancreatic cancer, whereas all four stage I patients had an abnormal (less than 5) T:DHT ratio. These results suggest that the T:DHT ratio is a useful marker for pancreatic cancer in males. It can be used alone or in combination with CA 19-9, and should be further evaluated in the differential diagnosis of patients with the early stages of this disease.
对21例男性胰腺癌患者及62例患有其他胃肠道恶性肿瘤或良性胰胆疾病的对照者的血清进行了睾酮：双氢睾酮比值（T:DHT）和抗原标志物CA 19-9的研究。T:DHT比值的特异性为98%，显著优于CA 19-9在37 U/ml临界值水平（61%）和100 U/ml（79%）时的特异性。T:DHT比值的敏感性为67%，而CA 19-9在上、下临界值水平时的敏感性分别为71%和90%。T:DHT比值的假阴性结果主要见于晚期胰腺癌患者，而所有4例I期患者的T:DHT比值均异常（小于5）。这些结果表明，T:DHT比值是男性胰腺癌的一个有用标志物。它可单独使用或与CA 19-9联合使用，并且应在该疾病早期患者的鉴别诊断中进一步评估。
